TY - JOUR 
A1 - Vicent, Lourdes
AU - Esteban Fernández, Alberto
AU - Gómez Bueno, Manuel
AU - Juan Bagudá, Javier de
AU - Díez Villanueva, Pablo
AU - Iniesta, Ángel Manuel
AU - Ayesta, Ana
AU - González Saldivar, Hugo
AU - Rojas González, Antonio
AU - Bover Freire, Ramón
AU - Iglesias del Valle, Diego
AU - García Aguado, Marcos
AU - Perea Egido, Jesus Ángel
AU - Martínez Sellés Oliveria Soares, Manuel
T1 - Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry
Y1 - 2019
SN - 0160-2446

UR - http://hdl.handle.net/11268/7890
AB - Sacubitril/valsartan (SV) is a new therapy in heart failure with reduced ejection fraction. Our aim was to determine the efficacy and safety of this drug daily clinical practice. We performed a multicenter registry in 10 hospitals. All patients who started SV from October 2016 to March 2017 on an outpatient basis were included. A total of 427 patients started treatment with SV. Mean follow-up was 7.0 ± 0.1 months. Forty-nine patients (11.5%) discontinued SV, and 12 (2.8%) died. SV discontinuation was associated with higher cardiovascular (hazard ratio 13.22, 95% confidence interval, 6.71-15.73, P < 0.001) and all-cause mortality (hazard ratio 13.51, 95% confidence interval 3.22-56.13, P < 0.001). Symptomatic hypotension occurred in 71 patients (16.6%). Baseline N-terminal pro-B-type natriuretic peptide levels, functional class, and left ventricular ejection fraction improved at the end of follow-up in patients who continued with SV (all P values ≤0.001). This improvement was not significant in patients with SV discontinuation. SV has a good tolerability in patients from daily clinical practice. SV withdrawal in patients with heart failure and reduced ejection fraction was independently associated with increased all-cause mortality. Patients who continued with SV presented an improvement in functional class left ventricular ejection fraction and N-terminal pro-B-type natriuretic peptide levels.
KW - Insuficiencia cardíaca
KW - Terapéutica
KW - Enfermedad cardiovascular
KW - Tratamiento médico
KW - Medicamento
LA - eng
ER -